Aberrant DNA hypermethylation is a hallmark of cancer although the underlying 37 molecular mechanisms are still poorly understood. To study the possible role of 5-38 hydroxymethylcytosine (5hmC) in this process we analyzed the global and locus-39 specific genome-wide levels of 5hmC in primary samples from 54 gliomas and 72 40 colorectal cancer patients. Levels of 5hmC in colorectal cancer were very low and no 41 consistent changes were detected between control tissues and tumors. As expected, 42 levels of 5hmC in non-tumoral brain samples were high and significantly reduced at the 43 49,601 CpG sites in gliomas. Strikingly, hypo-hydroxymethylation at 4,627 (9.3%) of 44 these CpG sites was associated with aberrant DNA hypermethylation. The DNA regions 45 containing these CpG sites were enriched in H3K4me2, and presented a different 46 genuine chromatin signature to that characteristic of the genes classically aberrantly 47 hypermethylated in cancer. We conclude that this data identifies a novel 5hmC-48 dependent non-canonical class of aberrant DNA hypermethylation in glioma. 
Introduction 52
DNA methylation at the fifth position of cytosine (5mC) has been one of the most 53 studied epigenetic modifications in mammals to date. 5mC is involved in the regulation 54 of multiple physiological and pathological processes, including cancer, and when 55 located at gene promoters, it is usually linked to transcriptional repression. 56
As distinctive features of tumorigenesis, local DNA hypermethylation and global 57 hypomethylation have been attributed to changes in 5mC levels [10; 11] . However, the 58 discovery a few years ago, of 5-hydroxymethylcytosine (5hmC), a new epigenetic mark 59 resulting from 5mC oxidation, is reshaping our view of the cancer epigenome [29; 47] . 60
This 5mC to 5hmC conversion in mammals is mediated by ten-eleven translocation 61 proteins (TET1, TET2, and TET3), a family of α-ketoglutarate (αKG) and Fe(II)-62 dependent dioxygenases [21; 47] . Global levels of 5hmC in the genome fluctuate 63 considerably according to tissue type, and are consistently around 10-fold lower than 64 those of 5mC, though it is interesting that the highest levels of both marks are found in 65 The fact that there are now methods available that distinguish 5mC and 5hmC positions 72 at single-base resolution within the genome prompted us to reassess the role of DNA 73 methylation status in tumorigenesis from a 5hmC perspective. The method used here 74 allowed us to describe global and genome-wide locus-specific 5mC and 5hmC patterns 75 in colon and brain samples, to identify a specific chromatin signature associated with 76 changes of these epigenetic marks in cancer and, most notably, to describe a novel non-77 canonical type of aberrant DNA hypermethylation in cancer. 78 Materials and Methods). A total of 49,601 CpG sites that were hypohydroxymethylated 147 were identified in gliomas, but almost no hyper-hydroxymethylated sites were found 148 (see Materials and Methods) ( Figure 3A and Supplementary Table 3 ). In contrast, no 149 significant methylation changes were found in colorectal tumors ( Figure 3A ) and thus 150 subsequent stages of the study focused on glioma alone. Hierarchical clustering using 151 the differentially hydroxymethylated CpG sites showed the correct classification of 152 normal and tumor samples ( Figure 3B ). The analysis of the genomic distribution of the 153 hypo-hydroxymethylated CpG sites in gliomas showed an enrichment at low CpG 154 density regions (Wilcoxon rank sum test, p<0.001, D=-0.41), and consequently at non-155
CpG islands (chi-squared test, p<0.001, OR=2.53) ( Figure 3C ). With respect to gene 156 location, hypo-hydroxymethylation was more frequent in introns (chi-squared test, 157 p<0.001, OR=1.77) ( Figure 3C) . 158
To identify possible chromatin signatures associated with DNA hypo-159 hydroxymethylation in gliomas, we compared our list of hypo-hydroxymethylated CpG 160 sites with previously published data on a range of histone modifications and chromatin 161 modifiers in 11 different cell types (see Materials and Methods) ( Figure 3D) . 162 Interestingly, this approach showed an enrichment of hypo-hydroxymethylation at 163 chromatin regions marked with the activating histone PTMs H3K4me1, H3K36me3, 164
H4K20me1 and H3K79me2 (Fisher's exact test, p<0.05) (Figure 3D ), but not with the 165 repressive histone modification H3K27me3, which has been previously shown to be 166 associated with aberrant DNA hypermethylation in cancer [38; 52] ( Figure 3D) . A 167 similar framework was used to test for the enrichment of our selected probes over the 168 computer-generated chromatin segmentation states from the ENCODE ChromHMM 169 project. Using this approach, we found that hypohydroxymethylated CpG sites were 170 significantly associated with transcription regulation and enhancers (Fisher's exact test; 171 p < 0.05) ( Figure 3E) . 172 173 DNA hypo-hydroxymethylation identifies a novel type of non-canonical aberrant 174
DNA hyper-methylation in glioma 175
To study the relationship between changes in 5mC and 5hmC in glioma, we first 176 Table 6) . 183
To investigate, at a functional genomic level, the characteristics of these two classes of 184 aberrantly hypermethylated CpG sites in gliomas we first analyzed their genomic 185 distribution in relation to density of CpG sites and we found that the hypermethylated 186
CpG sites that lose 5hmC (hyper5mC-hypo5hmC) were enriched in low density CpG 187 regions (Wilcoxon rank sum test, p<0.001, D=-0.11) as compared with the 188 hypermethylated CpG sites that showed no changes in 5hmC (hyper5mC) (Wilcoxon 189 rank sum test, p<0.001, D=-0.23) ( Figure 4B, Supplementary Tables 6 and 7) . In line 190 with this, hyper5mC-hypo5hmC sites were strongly depleted from CGIs (chi-squared 191 test, p<0.001, OR=0.42) ( Figure 4B ). Hierarchical clustering using the differentially 192 methylated CpG sites showed that the hyper5mC-hypo5hmC sites were slightly more 193 methylated in control brain samples than the hyper5mC sites, and that they were more 194 uniformly hypermethylated in glioma ( Figure 4C , and it appears that DNA hydroxymethylation might play a specific role in 270 cancer, in this work we aimed to re-evaluate changes in DNA methylation in cancer, 271 paying special attention to the specific contribution of 5hmC. 272
To identify the DNA regions affected by hydroxymethylation changes in cancer, we 273 first focused on four types of repeated DNA (LINE1, Sat α, NBL2 and ALUYB8). 274
Among them, the LINE1 repeat is of particular interest because it contains almost 20% 275 of the genomic 5mC, and it has been proposed to be a surrogate of global DNA 276 methylation [51]. Our results confirmed that tumors lose 5mC at repeated DNA [7] . 277
However, the level of 5hmC at repeated DNA in healthy samples was very low and no 278 significant differences were observed compared to tumors, which indicates that the 279 global DNA hypo-hydroxymethylation previously observed in cancer [23; 27; 28; 39] 280 does not principally occur at repeated DNA. As changes in 5hmC at repeated DNA 281 could not explain the global differences previously observed by mass spectrometry, we 282 decided to study the possible contribution of single copy sequences. Genome-wide 283 profiling of 5mC and 5hmC of healthy tissue identified a 10-fold increase in abundance 284 of CpG sites frequently hydroxymethylated in brain compared to colorectal tissue, 285 providing evidence that the level of this epigenetic mark is highly tissue type-286 dependent, and also that it is very abundant in the brain [16; 24; 29; 32; 37; 44]. 287
Moreover, 5hmC was enriched in regions with low CpG density and in introns in both 288 colorectal and brain tissue. As the 5hmC is enriched in different genomic regions, these 289 results support the notion that 5hmC is not simply a demethylation intermediate [1] . 290
Interestingly, 5hmC co-localized in regions marked with the activating histone PTM 291
H3K4me1. This histone mark has been previously associated with gene enhancers [20; 292 48], which suggests that DNA hydroxymethylation might play a role in gene regulation 293 in trans. Moreover, we have recently found an association between H3K4me1 and DNA 294 hypomethylation during aging in stem and differentiated cells [12] , which may 295 represent an interesting link between aging and cancer at these genomic regions. 296
Colorectal tumors showed more changes with respect to 5mC than to 5hmC. However, 297 in contrast, glioma presented more changes in 5hmC than in 5mC, suggesting that the 298 dynamics of DNA methylation and hydroxymethylation in cancer is highly tumor-type 299 dependent. Moreover, the great number of hypo-hydroxymethylated single CpG sites in 300 glioma could explain the global differences previously observed by mass spectrometry 301 [23; 27; 28; 39] and suggests that, in contrast to 5mC, most DNA hypo-302 hydroxymethylation in brain tumors occurs at single copy sequences. 303
The behavior of 5hmC led us to next identify two types of CpG sites aberrantly 304 hypermethylated in glioma: aberrantly hypermethylated CpG sites that showed no 305 changes in 5hmC; and hypermethylated CpG sites that lose 5hmC. The first of these 306 sites display similar chromatin signatures to previously described genes aberrantly 307 hypermethylated in cancer (i.e. enrichment in the repressive histone marks H3K9me3 308 and H3K27me3) [36; 38; 52]. In contrast, the second type of aberrantly 309 hypermethylated CpG sites were enriched in the activating histone PTMs H3K4me1, 310
H3K36me3, H3K79me2, H4K20me1 and H3K4me2. As these CpG sites present a 311 genuine chromatin signature which is different to the repressive chromatin signature of 312 the classical genes aberrantly hypermethylated in cancer [36; 38; 52], we conclude that 313 they represent a novel 5hmC-dependent non-canonical class of aberrant DNA 314 hypermethylation in glioma. As this gain in 5mC is inversely correlated with loss of 315 5hmC, it was not possible to identify this significant alteration in previous studies using 316 the classical sodium bisulfite-based technologies, since they are not able to distinguish 317 between the two chemical modifications. 318
Aberrant DNA hypermethylation in cancer was discovered more than 30 years ago, but 319 the underlying molecular mechanisms are still poorly understood. For example, it has 320 been proposed that genes enriched in bivalent histone modifications (H3K4me3 and 321 H3K27me3) and polycomb group proteins during embryo development are prone to 322 become aberrantly hypermethylated in cancer [36; 38; 52] but the molecular basis of 323 this is unknown. Our data suggest that tumor cells might in fact acquire aberrant DNA 324 methylation through various different pathways. Moreover, in the case of the non-325 canonical hypermethylation, the previous loss of 5hmC suggests that aberrant 326 hypermethylation at these DNA regions could be due to an attempt by the cell to reverse 327 or repair the loss of 5hmC at functionally sensible loci. This possibility is supported by 328 the fact that the non-canonical aberrant hypermethylation described here seems to play 329 an important role in gene regulation. Intriguingly, 5hmC at gene promoters has also 330 been proposed to protect from aberrant hypermethylation in colorectal cancer [50] . 331
Thus, although it seems that 5hmC plays an important role in the regulation of the DNA 332 methylation changes in cancer, more research is needed to fully understand its role. 333
The non-canonical aberrant hypermethylation described here seems to have a similar were also included in the model definition, but excluding those found to be correlated to 410 the phenotype of interest. P values were corrected for multiple testing using the 411 Benjamini-Hochberg method for controlling false discovery rate (FDR). An FDR 412 threshold of 0.001 was employed to determine differentially methylated and 413 hydroxymethylated probes. Additionally, these probes were filtered according to their 414 effect size, keeping only those probes with methylation or hydroxymethylation changes 415 between-groups which exceeded the median of all differences for the same comparison. 416
The probes without no significant 5hmC signal on control samples were filtered out 417 from the set of hypo-hydroxymethylated probes in glioma. 
Gap distance analysis 501
Distance to both the centromere and telomere was measured for each of the probes in 502 the HumanMethylation450 microarray. In order to find significant differences between 503 the probes within the subset of interest and those in the background, a Wilcoxon non-504 parametric test was used. Once again, a significance level of 0.05 was employed for all 505 tests, and Cliff's Delta (D) was used as a measure of effect size. 506 507
Microarray background correction 508
Although it is sometimes referred to as a genome-wide solution, the 509 HumanMethylation450 BeadChip only covers a fraction of the entire genome. In its 510 27K predecessor, the probes were mainly located at gene promoter regions, while the 511 newer HumanMethylation450 BeadChip additionally includes probes located inside 512 genes and in intergenic regions [4] . 513
The irregular distribution of probes can however lead to unwanted biases when studying 514 whether a selected subset of probes is enriched with respect to any functional or clinical 515 mark. For this reason, here a reference to the background distribution of features was 516 included in all statistical tests performed in order to prevent our conclusions from being 517 driven by the irregular distribution of probes. In qualitative tests (CGI status, genomic 518 region, or histone mark enrichment), the contingency matrix was built to represent the 519 background distribution of the microarray. In quantitative tests (CpG density, distance 520 to centromeres and telomeres) the corresponding metric was compared between the 521 subset of interest and the remaining probes in the microarray. Thus, any significant 522 result would indicate a departure from the fixed background distribution and ignore any 523 bias inherent in the test. In order to plot the CpG and histone peak information on the circular genome-wide and 541 example graphs, smoothing was applied to the data. CpG enrichment information for 542 canonical and non-canonical hypermethylation was generated by partitioning the 543 genome into intervals of 10kbp and assigning to each a score corresponding to the 544 average coverage of the selected CpGs in the interval. 545 546
Whole-genome bisulfite sequencing (WGBS) datasets 547
Supplementary data referenced in [42] was used as a validation dataset in glioblastoma. 548
Previously processed data in the form of quantified methylation for each CpG measured 549 in both strands of the genome was downloaded and filtered. Only methylation measures 550 from CpGs having a total read count higher than 10 were retained. 551
The resulting dataset comprised only two samples (normal and tumoral), so a 552 descriptive strategy was used to distinguish the different types of probes according to 553 their methylation status. Hydroxymethylated probes were identified as those having a 554 5hmC measure higher than 0.1. Differentially methylated probes were defined as those 555 having an absolute difference in their methylation values, between the control and 556 tumor samples, higher than a given threshold (0.2 for 5mC and 0.1 for 5hmC). 557
The validation datasets may contain either one or two methylation measures for each 558
CpG in the genome as they measure methylation in both strands. Strand-agnostic CpG 559 regions representing the CpG dinucleotides with at least one measure were defined in 560 order to compute the degree of intersection between the WGBS and methylation arrays 561 
